Feasibility of endoscopic treatment and predictors of lymph node metastasis in early gastric cancer

Table 3 Lymph node metastasis in early gastric cancer according to the endoscopic submucosal dissection indications

	LNM negative	LNM positive	LNM rate (%)	95%CI	P-value
Ab (n = 90)	90	0	0.0	0%-4.1%	0.021
Ex1 (n = 86)	83	3	3.5	0.75%-10.56%
Ex2 (n = 32)	31	1	3.1	0.08%-17.91%
Ex3 (n = 110)	110	0	0	0%-3.35%
Ex4 (n = 83)	83	0	0	0%-4.44%

Ex1: Differentiated mucosal tumors, ≤ 30 mm in size, without lymphovascular invasion (LVI), and with ulceration. Ex2: Differentiated mucosal tumors, without ulcer and LVI, and of any size. Ex3: Undifferentiated mucosal tumors without ulcer and LVI, and ≤ 20 mm in size. Ex4: Differentiated tumors with SM1 invasion, no LVI, and ≤ 30 mm in size. LNM: Lymph node metastasis; CI: Confidence interval; Ab: Absolute indications for endoscopic submucosal dissection; Ex: Expanded indications for endoscopic submucosal dissection.